[en] We prepared solutions of human IgM and IgG to various lipopolysaccharide (LPS) species. These were then tested, along with solutions of non-LPS specific human IgG or IgM, for their ability to confer passive immunity against experimental endotoxemia in two animal models. The immunoglobulins were first tested for an effect on the lethality induced by seven different LPSs in actinomycin-D sensitized mice, or by three different bacteria in normal mice. When the immunoglobulins were administered 1 h before challenge, a small protective effect was observed. This protection was dependent upon both the anti-LPS agent, the chemical composition of the LPS, or the strain of gram-negative bacteria used for injection. The anti-LPS IgM and IgG preparations reduced the mortality induced by Escherichia coli but not by Serratia marcescens or Klebsiella pneumoniae, indicating protection by strain-specific antibodies. When the antibodies were preincubated with LPS or bacteria for 30 min before administration, almost complete protection was seen. The influence of these immunoglobulin preparations or of human albumin (as a control) on the hypotensive and vascular-permeabilizing effects of LPS in rats was then studied. A dose-dependent inhibitory effect was observed with IgG preparations and albumin. At 200 mg/kg, anti-LPS IgG reduced the effects of LPS, while at 400 mg/kg, both anti-LPS and normal IgG preparations showed protection, as did human albumin used at the same dose. The IgM-enriched preparation worsened the initial hypotensive phase after LPS, whereas the anti-LPS IgM significantly reduced the second phase of the hypotension, but only at the largest dose of 400 mg/kg. In this second model using the rat, a clear difference between the activity of IgG and IgM was thus observed. We conclude that pretreatment with human immunoglobulins from large plasma pools modestly, but significantly, attenuated the effects of murine and rat Gram-negative sepsis, but that protection was incomplete. Our results suggest that single regimen intervention strategies may not be sufficient to influence the course of the disease.
Disciplines :
Anesthesia & intensive care
Author, co-author :
Nys, Monique ; Centre Hospitalier Universitaire de Liège - CHU > Soins intensifs
Damas, Jacques ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques
Damas, Pierre ; Université de Liège - ULiège > Soins intensifs
Laub, R.
Cloes, Jean-Michel
Lamy, Maurice ; Université de Liège - ULiège > Département des sciences cliniques > Anesthésie et réanimation
Language :
English
Title :
Study of the protective effects of hyperimmune immunoglobulins G and M against endotoxin in mice and rats
Abraham E, Raffin TA (1994) Sepsis therapy trials: continued disappointment or reason for hope? JAMA 271:1876-1878
Adam D, Gerlach B (1994) Antibacterial treatment of sepsis. In: Reinhart K, Eyrich K, Sprung C (eds) Sepsis: current perspectives in pathophysiology and therapy. Update in intensive care and emergency medicine, vol 18. Springer, Berlin Heidelberg New York, pp 246-255
Amura CR, Silverstein R, Morrison DC (1998) Mechanisms involved in the pathogenesis of sepsis are not necessarily reflected by in vitro cell activation studies. Infect Immun 66:5372-5378
Appelmelk BJ, Verweij-van Vught M, Brade H, Maaskant J, Schouten W, Thijs B, MacLaren D (1988) Protection, characterization and biological effects of monoclonal antibodies to different parts of the gram-negative lipopolysaccharide core region. Prog Clin Biol Res 272:373-382
Bailat S, Heumann D, Le Roy D, Baumgartner JD, Rietschel ET, Glauser MP, Di Padova F (1997) Similarities and disparities between core-specific and O-side-chain-specific antilipopolysaccharide monoclonal antibodies in models of endotoxemia and bacteremia in mice. Infect Immun 65:811-814
Baumgartner JD, McCutchan JA, Melle G, Vogt M, Luethy R, Ziegler EJ, Klauber MR, Muehlen E, Chiolero R, Geroulanos S (1985) Prevention of gram-negative shock and death in surgical patients with antibody to endotoxin core glycolipid. Lancet II:59-63
Bond RF (1985) Peripheral circulatory responses to endotoxin. In: Hinshaw LB (ed) Handbook of endotoxin, vol 2. Pathophysiology of endotoxin. Elsevier, North Holland, pp 36-75
Bone RC (1991) The pathogenesis of sepsis. Ann Intern Med 115:457-469
Calandra T, Glauser MP, Schellekens J, Verhoef J, Swiss-Dutch J5 Immunoglobulin Study Group (1988) Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized study. J Infect Dis 158:312-319
Centers of Disease Control (1990) Increase in national hospital discharge survey rates for septicemia - United States. 1979-1987. JAMA 263:937-938
Chapes SK, Beharka AA (1995) Lipopolysaccharide is required for the lethal effects of enterotoxin B after D-galactosamine sensitization. J Endotoxin Res 2:263-271
Cross AS (1994) Antiendotoxin antibodies: a dead end? Ann Intern Med 121:58-60
Cross AS, Opal S (1994) Therapeutic intervention in sepsis with antibody to endotoxin: is there a future? J Endotoxin Res 1:57-69
Cross AS, Sadoff JC, Opal SM, Cryz Jr. SJ, Bhattacharjee AK (1992) Immunotherapy for septic shock. A process-oriented approach. In: Sande MA, Root RK (eds) Contemporary issues in infectious diseases, vol 9. Churchill Livingstone, New York, pp 77-91
Damas J, Remacle-Volon G (1990) Platelets and the endotoxin shock in the rat. Life Sci Adv 9:125-133
David SA, Balaram P, Mathan VI (1995) Characterization of the interaction of lipid A and lipopolysaccharide with human serum albumin: implications for an endotoxin carrier function for albumin. J Endotoxin Res 2:99-106
Dofferhoff ASM, Buys J (1995) Effects of antibiotics on endotoxin release. In: Vincent J-L (ed) Yearbook of intensive care and emergency medicine. Springer, Berlin Heidelberg New York, pp 465-472
D'Orio V, Wahlen C, Rodriguez LM, Fossion A, Juchmes J, Halleux J, Marcelle R (1987) A comparison of Escherichia coli endotoxin single bolus injection with low-dose endotoxin infusion on pulmonary and systemic vascular changes. Circ Shock 21:207-216
Dunn DL, Ewald DC, Chandan N, Cerra FB (1986) Immunotherapy of gram-negative sepsis. A single murine monoclonal antibody provides cross-genera protection. Arch Surg 121:58-62
Eidelman LA, Sprung CL (1994) Why have new effective therapeutics for sepsis not been developed? Crit Care Med 20:1330-1334
Elliott GT, Welty D, Kuo YD (1991) The D-galactosamine loaded mouse and its enhanced sensitivity to lipopolysaccharide and monophosphoryl lipid A: a role for superoxide. J Immunother 10:69-74
Fomsgaard A, Holder IA (1993) Effect of a human IgG preparation rich in antibodies to a wide range of lipopolysaccharides on gram-negative bacterial sepsis in burned mice. APMIS 101:229-234
Fomsgaard A, Baek L, Fomsgaard JS, Engquist A (1989) Preliminary study on treatment of septic shock patients with anti-lipopolysaccharide IgG from blood donors. Scand J Infect Dis 21:697-708
Galanos C, Freudenberg MA (1993) Bacterial endotoxin: biological properties and mechanisms of action. Med Inflamm 2:11-16
Ge Y, Ezzele RM, Tompkins RG, Warren HS (1994) Cellular distribution of endotoxin after injection of chemically purified lipopolysaccharide differs from that after injection of live bacteria. J Infect Dis 169:95-104
Greenman RL, Schein RMH, Martin MA, Wenzel RP, MacIntyre NR, the XOMA Sepsis Study Group (1991) A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin, the treatment of gram-negative sepsis. JAMA 266:1097-1102
Hamill RJ, Maki DG (1986) Endotoxin shock in man caused by gram-negative bacilli. Etiology, clinical features, diagnosis, natural history and prevention. In: Proctor RA (ed) Handbook of endotoxin. Elsevier, North Holland, pp 55-126
Hurley JC (1992) Antibiotic-induced release of endotoxin: a preappraisal. Clin Infect Dis 15:840-854
Johns MA, Bruins SC, McCabe WR (1977) Immunization with R mutants of Salmonella minnesota. II. Serological response to lipid A and the lipopolysaccharide of Re mutants. Infect Immun 17:9-14
Knaus WA, Wagner DP, Harrell FE, Draper EA (1994) What determines prognosis in sepsis? Evidence for a comprehensive individual patient risk assessment approach to the design and analysis of clinical trials. In: Reinhart K, Eyrich K, Sprung C (eds) Sepsis: current perspectives in pathophysiology and therapy. Update in intensive care and emergency medicine, vol 18. Springer, Berlin Heidelberg New York, pp 23-37
Kuida H, Gilbert RP, Hinshaw LB, Brunson JG, Visscher MB (1961) Species differences in effect of Gram-negative endotoxin on circulation. Am J Physiol 200:1197-1202
Lagente V, Fortes ZB, Garcia-Leme J, Vargaftig BB (1988) PAF-acether and endotoxin display similar effects on rat mesenteric microvessels: inhibition by specific antagonists. J Pharmacol Exp Ther 247:254-261
Luderitz O, Staub AM, Westphal O (1966) Immunochemistry of O and R antigens of Salmonella and related Enterobacteriaceae. Bacteriol Rev 30:192-225
Lynn WA, Cohen J (1995) Adjunctive therapy for septic shock: a review of experimental approaches. Clin Infect Dis 20:143-158
McCloskey RV, Straube RC, Sanders C, Smith CR, the CHESS trial study group (1994) Treatment of septic shock with human monoclonal antibody HA-1A: a randomized, double-blind, placebo-controlled trial period. Ann Intern Med 120:1-5
McConnell JS, Appelmelk BJ, Cohen J (1990) Dissociation between Limulus neutralisation and in vivo protection in monoclonal antibodies directed against endotoxin core structures. Microb Pathog 9:55-59
McCuskey RS, McCuskey RA, Urbaschek R, Urbaschek B (1984) Species differences in Kupffer cells and endotoxin sensitivity. Infect Immun 45:278-280
McCutchan JA, Wolf JL, Ziegler EJ, Braude AI (1983) Ineffectiveness of single-dose human antiserum to core glycolipid (Escherichia coli J5) for prophylaxis of bacteremic gram-negative infection in patients with prolonged neutropenia. Schweiz Med Wochenschr 113 [Suppl 14]:40-55
Morrison DC, Danner RL, Dinarello CA, Munford RS (1994) Bacterial endotoxins and pathogenesis of gram-negative infections: current status and future direction. J Endotoxin Res 1:71-83
Neely AN, Orloff MM, Imwalle AR, Holder IA (1995) A murine model for studying endotoxemia and the efficacy of anti-LPS agents in an immunocompromised host. J Endotoxin Res 2:115-120
Nys M, Cloes J-M, Demonty J, Joassin L (1990) Protective effects of polyclonal sera and of monoclonal antibodies active to Salmonella minnesota Re595 lipopolysaccharide during experimental endotoxemia. J Infect Dis 162:1087-1095
Nys M, Laub R, Damas P, Sondag D, Goethals T, Jamaer D, Joassin L, Lamy M (1996) Screening and characterization of specific anti-lipopolysaccharide antibodies in Belgian blood donors by enzyme-linked immunosorbent assays. Eur J Clin Invest 26:1134-1142
Opal SM (1995) Clinical trials of novel therapeutic agents: why did they fail? In: Vincent J-L (ed) Yearbook of intensive care and emergency medicine. Springer, Berlin Heidelberg New York, pp 425-436
Parillo JE (1993) Pathogenetic mechanisms of septic shock. N Engl J Med 328:1471-1477
Pollack M (1990) New therapeutic strategies in gram-negative sepsis and septic shock based on molecular mechanisms of pathogenesis. In: Mandell GL, Douglas RG, Bennett JE (eds) Principes and practices of infectious diseases, update 8. Churchill Livingstone, New York, pp 1-18
Raetz CRH (1990) Biochemistry of endotoxins. Annu Rev Biochem 59:129-170
Reed LJ, Muench J (1938) A simple method of estimating fifty per cent end points. Am J Hyg 27:494-497
Sanchez-Cantu L, Rode HN, Yun TJ, Christou NV (1991) Tumor necrosis factor alone does not explain the lethal effect of lipopolysaccharide. Arch Surg 126:231-235
Schedel I, Dreikhausen U, Nentwig B, Hockenschnieder M, Rauthmann D, Balikcioglu S, Coldewey R, Deicher H (1991) Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. Crit Care Med 19:1104-1113
Shenep JL, Mogan KA (1984) Kinetics of endotoxin release during antibiotic therapy for experimental gram-negative bacterial sepsis. J Infect Dis 150:380-388
Shnyra A, Hultenby K, Linberg AA (1993) Role of the physical state of Salmonella lipopolysaccharide in expression of biological and endotoxic properties. Infect Immun 61:5351-5360
The Intravenous Immunoglobulin Collaborative Study Group (1992) Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high-risk of postsurgical infection. N Engl J Med 327:234-240
Wallace JL, Steel G, Whittle BJR, Lagente V, Vargaftig B (1987) Evidence for platelet-activating factor as a mediator of endotoxin-induced gastrointestinal damage in the rat. Gastroenterology 93:765-773
Warren HS, Danner RL, Munford RS (1992) Anti-endotoxin monoclonal antibodies. N Engl J Med 326:1153-1157
Wenzel R, Bone R, Fein A, Quenzer R, Schentag J, Gorelick KJ, Wedel N, Perl T (1991) Results of a second, double-blind randomized, controlled trial of antiendotoxin antibody E5 in gram-negative sepsis. Antimicrob Agents Chemother 294:1170
Wenzel RP, Andriole VT, Bartlett JG, Batt MD, Bullock WE, Coons CG, Light B, Martin MA, Sanford J, Sande MA (1992) Antiendotoxin monoclonal antibodies for gram-negative sepsis: guidelines from the IDSA. Clin Infect Dis 14:973-976
Winkelhake JL, Gauny SS, Senyk G, Piazza D, Stevens P (1992) Human monoclonal antibodies to glycolipid A that exhibit complement species-specific effector functions. J Infect Dis 165:26-33
Young LS, Gascon R, Alam S, Bermudez LEM (1989) Monoclonal antibodies for treatment of gram-negative infections. Rev Infect Dis 11:1564-1571
Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Douglas H, Braude AI (1982) Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 307:1225-1230
Ziegler EJ, Fisher JC Jr, Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NNH, Allen IE, Berger HJ, Knatterud GL, Lobuglio AF, Smith CR, the HA-1A sepsis study group (1991) Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin a randomized, double-bind, placebo-controlled trial. N Engl J Med 324:429-436